A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

September 30, 2011

Conditions

Neoplasms, Malignant

Interventions

DRUG

Ombrabulin (AVE8062)

"Pharmaceutical form:concentrate solution~Route of administration: intravenous infusion"

Trial Locations (1)

Sanofi-Aventis Administrative Office, Brussels